[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200870141A1 - Комбинационная терапия с использованием антител к egfr и her2 - Google Patents

Комбинационная терапия с использованием антител к egfr и her2

Info

Publication number
EA200870141A1
EA200870141A1 EA200870141A EA200870141A EA200870141A1 EA 200870141 A1 EA200870141 A1 EA 200870141A1 EA 200870141 A EA200870141 A EA 200870141A EA 200870141 A EA200870141 A EA 200870141A EA 200870141 A1 EA200870141 A1 EA 200870141A1
Authority
EA
Eurasian Patent Office
Prior art keywords
her2
antibodies
egfr
cancer
receptors
Prior art date
Application number
EA200870141A
Other languages
English (en)
Other versions
EA015173B1 (ru
Inventor
Стефен Д. Джиллиз
Давид Азрия
Кристель Ларбуре
Андре Пелегрин
Original Assignee
Мерк Патент Гмбх
Юниверсити Оф Монпелье 1
Л'Институт Насиональ Де Ля Санте Эт Де Ля Решерш Медикаль
Сентр Режиональ Де Лютт Контр Ле Кансер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200870141(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Патент Гмбх, Юниверсити Оф Монпелье 1, Л'Институт Насиональ Де Ля Санте Эт Де Ля Решерш Медикаль, Сентр Режиональ Де Лютт Контр Ле Кансер filed Critical Мерк Патент Гмбх
Publication of EA200870141A1 publication Critical patent/EA200870141A1/ru
Publication of EA015173B1 publication Critical patent/EA015173B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к комбинированному применению антител к EGFR и антител к HER2 для лечения рака, особенно подходящему для рака, экспрессирующего высокие уровни EGFR и низкие уровни HER2. Изобретение имеет отношение, в частности, к моноклональным антителам «trastuzumab» (HERCEPTIN®), нацеленным на рецепторы HER2, эффективность которых может быть значительно повышена in vivo путём комбинирования с моноклональными антителами «matuzumab» (hmAb 425, EMD 72000), нацеленными на рецепторы EGF. Комбинационное лечение пригодно для пациентов, страдающих раком, имеющим указанные характеристики экспрессии рецепторов, предпочтительно раком поджелудочной железы.
EA200870141A 2006-01-04 2006-12-15 Комбинированная терапия с использованием антител к egfr и her2 EA015173B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06000107 2006-01-04
PCT/EP2006/012133 WO2007076923A1 (en) 2006-01-04 2006-12-15 Combination therapy using anti-egfr and anti-her2 antibodies

Publications (2)

Publication Number Publication Date
EA200870141A1 true EA200870141A1 (ru) 2009-02-27
EA015173B1 EA015173B1 (ru) 2011-06-30

Family

ID=37876938

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870141A EA015173B1 (ru) 2006-01-04 2006-12-15 Комбинированная терапия с использованием антител к egfr и her2

Country Status (13)

Country Link
US (2) US20090214541A1 (ru)
EP (1) EP1968633B2 (ru)
JP (1) JP2009522316A (ru)
KR (1) KR20080110987A (ru)
CN (1) CN101365486B (ru)
AR (1) AR059127A1 (ru)
AU (1) AU2006332212B8 (ru)
BR (1) BRPI0620888A2 (ru)
CA (1) CA2636074A1 (ru)
EA (1) EA015173B1 (ru)
MX (1) MX2008008564A (ru)
WO (1) WO2007076923A1 (ru)
ZA (1) ZA200806723B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DE60234094D1 (de) 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
MX2009007987A (es) 2007-01-25 2010-03-01 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
MX2009009782A (es) 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
WO2009023265A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
NZ586544A (en) * 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
EP2324061B1 (en) 2008-09-03 2017-04-12 F. Hoffmann-La Roche AG Multispecific antibodies
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
WO2010120514A2 (en) * 2009-03-31 2010-10-21 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
CA2781682A1 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP2710038B1 (en) 2011-05-16 2018-01-17 Yeda Research and Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
EP2844675B1 (en) 2012-05-02 2019-01-02 Symphogen A/S Humanized pan-her antibody compositions
US10562974B2 (en) 2013-03-13 2020-02-18 University Of Kentucky Research Foundation Methods of administering IgG1 antibodies and methods of suppressing angiogenesis
WO2014139131A1 (en) 2013-03-14 2014-09-18 Crown Bioscience, Inc. Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
EP3693397B1 (en) * 2013-07-11 2024-06-12 The Scripps Research Institute Coiled coil immunoglobulin fusion proteins and compositions thereof
MX2016006301A (es) 2013-11-13 2016-12-16 Zymeworks Inc Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
MY193723A (en) * 2014-08-29 2022-10-27 Hoffmann La Roche Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
JP2018062980A (ja) * 2016-10-12 2018-04-19 株式会社ジェイテクト ボールネジ装置、ボールネジ装置の製造方法及びステアリング装置
US20180221481A1 (en) * 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
CN117915950A (zh) * 2021-08-06 2024-04-19 甘李药业股份有限公司 一种多特异性抗体及其用途
CN117430707B (zh) * 2023-10-25 2024-04-19 重庆天科雅生物科技有限公司 一种cik细胞的制备方法及其在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
HU219537B (hu) 1991-03-06 2001-05-28 Merck Patent Gmbh. Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
MXPA05003795A (es) * 2002-10-10 2005-06-08 Merck Patent Gmbh Composiciones farmaceuticas dirigidas a receptores erb-b1.
CN1953768B (zh) * 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her

Also Published As

Publication number Publication date
BRPI0620888A2 (pt) 2011-11-29
AR059127A1 (es) 2008-03-12
EP1968633B2 (en) 2017-11-01
AU2006332212A1 (en) 2007-07-12
ZA200806723B (en) 2009-09-30
CN101365486B (zh) 2012-10-31
WO2007076923A1 (en) 2007-07-12
US20150132308A1 (en) 2015-05-14
EA015173B1 (ru) 2011-06-30
US20090214541A1 (en) 2009-08-27
AU2006332212B2 (en) 2013-03-28
EP1968633A1 (en) 2008-09-17
AU2006332212B8 (en) 2013-05-30
CA2636074A1 (en) 2007-07-12
MX2008008564A (es) 2009-01-29
EP1968633B1 (en) 2014-02-12
KR20080110987A (ko) 2008-12-22
US9522956B2 (en) 2016-12-20
JP2009522316A (ja) 2009-06-11
CN101365486A (zh) 2009-02-11

Similar Documents

Publication Publication Date Title
EA200870141A1 (ru) Комбинационная терапия с использованием антител к egfr и her2
UA94899C2 (ru) Фиксированное дозирование антител к her
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
GEP20135917B (en) Stabilized polypeptide compositions
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
MY150756A (en) Tumor theraphy with an anti-vegf antibody
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
RU2012138703A (ru) Терапевтические и диагностические способы с применением анти-cd200 антител
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
UA92504C2 (en) Anti-myostatin monoclonal antibody
EA201100923A1 (ru) Антитела человека против тканевого фактора
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
MX358728B (es) Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
NZ595235A (en) Compositions and methods for increasing muscle growth
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2010022736A3 (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ604003A (en) Monoclonal antibodies against her2
MY160892A (en) Antibodies to ccr2
ATE557042T1 (de) Anti-myostatin-antikörper
NZ594682A (en) Fully human antibodies specific to cadm1
NZ611269A (en) Neutralizing anti-ccl20 antibodies

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU